Article Summary

This article covers a recent court ruling that restricts access to the abortion pill mifepristone by overturning FDA policies that allowed it to be mailed. It highlights concerns from pharmaceutical companies, doctors, and advocacy groups that the decision undermines medical science, disrupts access to abortion and other treatments, and could set a dangerous precedent for political interference in drug regulation. The tone emphasizes urgency and risk to established healthcare practices.